menu
    • menu
    [{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Persica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Persica Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Persica Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Persica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Persica Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Persica Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Micron Research Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Persica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Persica Pharmaceuticals \/ Micron Research Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Persica Pharmaceuticals \/ Micron Research Ltd"},{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Micron Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PP353","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Persica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Persica Pharmaceuticals \/ Micron Research","highestDevelopmentStatusID":"7","companyTruncated":"Persica Pharmaceuticals \/ Micron Research"}]

    Find Clinical Drug Pipeline Developments & Deals by Persica Pharmaceuticals

    Menu

    Persica Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Persica Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Persica Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linezolid

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Persica’s PP353 Phase 1b Shows Promise for Chronic Low Back Pain

                            Details : PP353 is an antibiotic formulation designed for intradiscal injection under image guidance. It is being evaluated for the treatment of chronic lower back pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 05, 2025

                            Lead Product(s) : Linezolid

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Persica Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Persica Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linezolid

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Persica Pharmaceuticals Completes Recruitment for Chronic Pain Trial

                            Details : PP353 is an antibiotic formulation for intradiscal injection, under evaluation for chronic lower back pain treatment by delivering targeted antibiotic exposure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 07, 2024

                            Lead Product(s) : Linezolid

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Persica Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Persica Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linezolid

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Micron Research Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Persica Pharmaceuticals has Completed the First Stage of Its Clinical Trial on Unique Injectable PP353, To Tre...

                            Details : PP353 is a sustained release formulation of an antibiotic to treat the chronic disc infection, which is designed for intradiscal injection under image guidance.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 19, 2021

                            Lead Product(s) : Linezolid

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Micron Research Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Persica Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Persica Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PP353

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Micron Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Persica 002 Phase 1b PP353 vs Placebo in the Treatment of Low Back Pain

                            Details : PP353 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Low Back Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 23, 2020

                            Lead Product(s) : PP353

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Micron Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth